Transforming Life Trajectories
of Children with Chronic Conditions
Who we are
Ludocare is a French start-up, and a pioneer in pediatric digital therapeutics, founded in 2017 in Lyon.
Our mission is to empower young patients from an early age with the skills and habits needed to manage their treatment and condition effectively, in order to sustainably improve their health and quality of life.
Our Digital Therapeutics are designed to engage both children and their parents through a connected and interactive approach. By combining medical efficacy and playful learning, we enhance pathologies’ control and foster stronger involvement from the whole family.
Pediatric Asthma: A Major Public Health Challenge
Asthma is the most prevalent chronic respiratory disease globally, affecting over 300(1) million individuals across all age groups and ethnicities, according to the World Health Organization. It is also the most common chronic disease in childhood, with an estimated global prevalence of approximately 12%. Although inhaled treatments exist to control the symptoms, their effectiveness is often compromised by:
- Poor treatment compliance
- Frequent errors in the use of inhalation devices
- Improper inhalation techniques(2)
This complex and often poorly controlled disease has a significant impact on:
- Children’s health: Frequent asthma attacks can cause irreversible lung damage and may even be life-threatening.
- Their schooling: Asthma is the leading cause of school absenteeism.
- The quality of life of children and parents: The disease disrupts sleep, limits physical activities, affects family and social relationships, and places a heavy mental burden on parents.
Addressing this challenge requires an innovative approach that shifts asthma management from reactive care to proactive and personalized interventions.
Sources :
- Asher I, Pearce N. Global burden of asthma among children. Int J Tuberc Lung. Dis. (2014) 18:1269–78. doi: 10.5588/ijtld.14.0170
- Valery Trosini-Desert, MD, Helene Lafoeste, MD,Lucile Regard, MD,Roxane Malrin, MD, Maria- Alejandra Galarza-Jimenez, MD, Cristina Esteban Amarilla, MD et al. A Telemedicine Intervention to Ensure the Correct Usage of Inhaler Devices. MARY ANN LIEBERT, INC. Telemedicine and e- HEALTH. 2020. Volume 26, No 11; P.1-9
JOE Digital Therapeutic
Children’s best ally to control asthma
To help children gain better control over their asthma, Ludocare has developed JOE, an innovative digital therapeutic (DTx) specifically designed for pediatric care. JOE is a connected medical device that offers personalized support for managing daily asthma treatments in children.
The system includes an interactive companion for the child and a mobile app for parents. Once the child’s treatment plan is set up in the parental app, JOE takes over the daily routine: it reminds the child to take their medication, guides them through proper inhalation techniques, and encourages consistent, healthy habits that support long-term asthma control.
JOE promotes adherence to prescribed treatments through fun, age-appropriate educational content and an engaging user experience. It transforms medication time into an interactive and empowering moment for children—helping them take control of their health.
JOE Digital Therapeutic is available by prescription for children with persistent asthma.
Discover JOE in action
The Four Pillars of JOE Digital Therapeutic : Supporting Children and Families Every Step of the Way
Asthma JOECARE Study
Proven Clinical Effectiveness
The JOE Digital Therapeutic was evaluated as part of the Asthma JOECARE study, a randomized phase 3 clinical trial conducted in France among children aged 4 to 11 years with persistent asthma of moderate to severe intensity, corresponding to grades 2 to 5 of the GINA classification.
Conducted across 17 hospital and private centers throughout France, the study followed 213 children.
Thanks to this study, LUDOCARE demonstrated the effectiveness of its Digital TherapeuticJOE, by reducing the number of severe asthma attacks in children aged 7 to 11.
Click here to read our press release on the clinical study results.
Participating centers
Real-World Adoption
Widespread Use in France and Positive Feedback
As part of a large-scale two-year program conducted in France from 2023 to 2024, Ludocare enabled over 750 children with persistent asthma to benefit from the JOE Digital Therapeutic,, through the involvement of 150 prescribing physicians.
An independent survey conducted in 2025 among 53 ambassador physicians confirmed the adoption of the solution:
- 96% of physicians recommend JOE
- 3 out of 4 parents accept the prescription of JOE during the initial consultation
- Satisfaction scores: 7.7/10 (physicians) – 7.5/10 (families)
JOE is recognized as a daily therapeutic ally, a playful companion, and a valuable innovation for better managing pediatric asthma before considering more complex treatments. JOE is easy to use and has no contraindications or drug interactions. It is not perceived as an additional treatment, but as a true companion.
Source
Independent quantitative, prospective and anonymized survey, conducted by the company HARRIS INTERACTIVE with 53 doctors in 2025, aimed at evaluating perceptions and practices in the use of Digital Therapeutic JOE.
Testimonials from Physicians and Families:
Our partners
